Headlines Covid-19 Specialties Trending Feeds Videos

Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory...

Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response against SARS-CoV-2 is unknown. Thus, we analyzed responses to...

On May 25, 2021, positive topline results from the phase III OCEAN study (NCT03151811) of melphalan flufenamide (melflufen) for the treatment of relapsed/refractory multiple...

The IMWG Developed Biobank Enhances Myeloma Research In this episode, myeloma expert Dr. Brian...

COVID-19 mRNA vaccines are highly efficacious in preventing COVID-19 morbidity and mortality in phase 3 clinical studies as well as in real-world settings. Emerging...